Clinical Trial News and Research

RSS

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.

18 Dec 2015

Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

A team of scientists at the University of Nebraska Medical Center (UNMC) and Longevity Biotech, Inc., has demonstrated that neuroprotection could be attained in preclinical models by a novel drug candidate that changes immune responses.

18 Dec 2015

Case Western scientist to lead a pair of studies to develop more effective treatment for CF

A scientist at Case Western Reserve University Frances Payne Bolton School of Nursing will lead a pair of studies to develop more effective treatment for symptoms of cystic fibrosis (CF), a life-threatening genetic disease that causes persistent lung infections and progressively limits the ability to breathe.

18 Dec 2015

Anti-aging Glycopeptide can improve efficacy of cell transplant treatments for diabetes patients

An antifreeze glycopeptide that mimics a naturally occurring glycoprotein found in Arctic fish is helping to significantly improve the efficacy of cell transplant treatments for diabetes patients--a procedure that transplants insulin producing islets to render them insulin independent for periods of time.

18 Dec 2015

Study examines effect of nonoperative treatment for appendicitis

It is too early to change the standard treatment of appendicitis in U.S. adults to initial antibiotic therapy only, rather than surgical removal of the appendix, or appendectomy, authors of a new systematic review study conclude.

18 Dec 2015

Stem cell therapy not significantly better than conventional treatment for Crohn's disease

A clinical trial to test the effectiveness of a stem cell therapy among adults with difficult to treat Crohn's disease has found it is not significantly better than conventional treatment in producing sustained disease remission after one year.

18 Dec 2015

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore.

17 Dec 2015

Ketogenic diet may be effective in treating schizophrenia

Research by James Cook University scientists has found a diet favoured by body-builders may be effective in treating schizophrenia.

17 Dec 2015

Active surveillance may be a viable treatment for select DCIS patients

Active surveillance could be a viable alternative to surgery and radiation for select patients with ductal carcinoma in situ, or DCIS, according to a mathematical model developed by researchers at Duke University.

17 Dec 2015

Louisville researchers move closer to potential treatment for gum disease

University of Louisville researchers recently received a patent on a synthetic biochemical compound and its variants, moving science closer to a treatment for gum disease. This discovery could lead to the formulation of a mouth rinse or tooth varnish to prevent the pathogen, P. gingivalis from colonizing in the mouth and establishing itself orally.

17 Dec 2015

Surgery more effective than drug therapy in patients with tertiary hyperparathyroidism

A study led by researchers from the Nephrology group at Bellvitge Biomedical Research Institute (IDIBELL) and the University Hospital of Bellvitge (HUB), compared the results of surgery with drug therapy in patients with tertiary hyperparathyroidism, ie after a kidney transplant.

17 Dec 2015

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer.

16 Dec 2015

Array BioPharma reports top-line results from binimetinib Phase 3 trial in patients with NRAS-mutant melanoma

Array BioPharma today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study met its primary endpoint of improving progression-free survival (PFS) compared with dacarbazine treatment.

16 Dec 2015

Major clinical trial launched to test ways to slow or halt mental decline in seniors

Some decline in memory and cognitive function is a normal part of aging, but what if it could be prevented? Researchers at University of California, San Diego School of Medicine and Washington University in St. Louis have launched a major clinical trial to investigate whether mental decline in seniors can be slowed or halted through exercise and other health-related interventions.

16 Dec 2015

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA).

15 Dec 2015

ESSA reports net loss of $11.5 million for year ended September 30, 2015

ESSA Pharma Inc. today reported financial results for the year ended September 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with International Financial Reporting Standards ("IFRS").

15 Dec 2015

Viralytics announces completion of $28 million placement

Viralytics Limited announces that it has completed a placement of 46,118,270 shares to international and domestic sophisticated or professional investors at an issue price of $0.615 per share to raise $28,362,736.

14 Dec 2015

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium, for the phase 3 registrational trial of its cancer immunotherapy ICT-107 in patients with newly diagnosed glioblastoma.

14 Dec 2015

Bracket announces new update to Randomization and Trial Supply Management product

Bracket, a leading clinical trial specialty services provider, announced this week an important new update to its Randomization and Trial Supply Management product. Mobile patient reminders, delivered via SMS text messaging, are now available as a core component of Bracket's RTSM 4.0 platform.

14 Dec 2015

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Cancer, it could be said, grows like a weed: rapidly, invasively, and with devastating impact on the place it infests. Also like a weed, cancer can't grow on its own — it needs nourishment, which it drains from the human body, just as weeds take nutrients in the soil away from other plants.

13 Dec 2015

Clinical Trial News and Research

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

Case Western scientist to lead a pair of studies to develop more effective treatment for CF

Anti-aging Glycopeptide can improve efficacy of cell transplant treatments for diabetes patients

Study examines effect of nonoperative treatment for appendicitis

Stem cell therapy not significantly better than conventional treatment for Crohn's disease

Novel strategies on the way for difficult-to-treat head and neck cancer

Ketogenic diet may be effective in treating schizophrenia

Active surveillance may be a viable treatment for select DCIS patients

Louisville researchers move closer to potential treatment for gum disease

Surgery more effective than drug therapy in patients with tertiary hyperparathyroidism

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Array BioPharma reports top-line results from binimetinib Phase 3 trial in patients with NRAS-mutant melanoma

Major clinical trial launched to test ways to slow or halt mental decline in seniors

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

ESSA reports net loss of $11.5 million for year ended September 30, 2015

Viralytics announces completion of $28 million placement

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

Bracket announces new update to Randomization and Trial Supply Management product

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer